FY2024 EPS Estimates for Illumina Raised by Leerink Partnrs
Stock analysts at Leerink Partnrs increased their FY2024 earnings estimates for Illumina in a research report issued to clients and investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda ...
Leerink Partnrs Has Bullish Outlook for SRPT FY2024 Earnings
Investment analysts at Leerink Partnrs upped their FY2024 earnings per share (EPS) estimates for Sarepta Therapeutics in a report issued on Monday, January 20th. Leerink Partnrs analyst J. Schwartz ...
RBC Capital Sticks to Its Buy Rating for Sarepta Therapeutics (SRPT)
In a report released on January 21, Brian Abrahams from RBC Capital maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...